CD274 and skin squamous cell carcinoma: Clinical trials, including the landmark EMPOWER-CSCC-1 trial (n = 78), have demonstrated efficacy across metastatic and locally advanced cSCC cohorts with an ORR of 47%, CR rate of 6.7%, and tolerability, irrespective of PD-L1 expression status [86,87,88,89].